<DOC>
	<DOCNO>NCT01780987</DOCNO>
	<brief_summary>The purpose study investigate safety apixaban Japanese acute DVT/PE subject symptomatic DVT/PE subject treat 10 mg BID apixaban 7 day initial therapy follow 5 mg BID apixaban 23 week long-term therapy ( total treatment period 24 week )</brief_summary>
	<brief_title>AStudy To Evaluate Safety And Eficacy Of Apixaban In Japanese Acute Deep Vein Thrombosis ( DVT ) And Pulmonary Embolism ( PE ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Acute symptomatic proximal DVT evidence proximal thrombosis Acute symptomatic PE evidence thrombosis segmental proximal branch Active bleed high risk bleed contraindicate treatment UFH VKA . Uncontrolled hypertension : systolic blood pressure &gt; 180 mm Hg diastolic blood pressure &gt; 110 mm Hg Subjects require dual antiplatelet therapy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>DVT</keyword>
	<keyword>PE</keyword>
	<keyword>VTE</keyword>
</DOC>